AI Diagnostic system to detect Diabetic Retinopathy

Analyzed report in 1 minute for 1$

Try Now

Experience the beta version now….

The uniqueness of Ophtha lies in its non-harmfulness, affordability, high content of information, and it can categorize eye problems in five different stages based on a grading system called ETDRS & disease-related feature segmentation techniques.

Try Now

Why Choose Ophtha AES?

Ophtha AES

AI Eye Screening System

  • As your Eyes be the windows to the world, AI based solutions are being designed, developed and trained to diagnose retinal associated diseases and disorders to treat populace for an affordable cost yet with accurate results. Thus, OPHTHA AES is capable of detecting conditions (automatically segmenting of pathological features) related to DR and detecting the existence of DR and pathological features (exudates, hemorrhages, microaneurysms, neovascularization) based on which the classification is done.
 Watch Video

Our Mission

To realize a day where each and everyone on the planet can afford and access modern technological products to lead a healthier life

Our Vision

To innovate AI-driven predictive and preventive solutions with the right fusion of advanced diagnostics to save and improve more human lives



From retinal image screening to grading for DR standards to reporting and flagging, our system operates as a fully autonomous solution.


Our solution offers you with results of high performance figures including 87.7% validation accuracy and 81.1% test accuracy.


Your data is secured and confidential with us as Ophtha AES uses novel and effective encryption and decryption technologies end-to-end, with highest level of compliance.

Our Achievements

Ophtha AES was awarded as the first runner up in “Sirasa Kotiyak Watina Adahasak” competition in 2018

2018 – Kotiyak Watina Adahasak – First Runner Up

We have been selected to final 20 round of Seedstars Sri Lanka, startup competition in 2019.

2019 – Seedstar Local – Sri Lanka Final 20

Out of 130 applications, in 2021, we have been selected for seed funding of 1.5 million LKR by Spirilation by being among final 20.

2021- Spirilation by ICTA

Out of 60 applications, in 2021, we have been selected for seed funding of 1.5 million LKR by SLTMobitel Entrepreneurship Studio by being among final 20.

2021 - SLTMobitel Entrepreneurship Studio

Commonwealth Digital Health Awards Sri Lanka

2022 Jury Special Mentioning, Ophtha

Runners up - Best disruptive innovation - Western Province

2023 Slasscom National Ingenuity Awards

Our Team

Akira Ikeda


Keerthi Kodithuwakku


Shashika Chamod


Dr.Dhanushi Hettiarachchi -


Our Publications

Read success stories of customers who used our products and solutions to achieve their business goals

A Rule based Approach for Hemorrhage Detection in Digital Fundus Photographs

Hemorrhages are one of the earliest signs of Diabetic Retinopathy, hence accurate detection of hemorrhages is crucial in an automated DR detection system. In this paper, a novel and robust rule based methodology for automated detection of hemorrhages is proposed. We present an ensemble technique for hemorrhage classification by incorporating size-based classification, color-statistic-based classification, and shape-based classification along with a novel dual step filtering approach for candidate detection. Finally, we present an experimental study carried out on DIARETDB database using the proposed method to detect and segment hemorrhages in retinal images.

A Novel Method of Detecting Neovascularization Regions in Digital Fundus Photographs

Neovascularization is one of the retinal signs we see in the proliferative stage of diabetic retinopathy (DR). Fundus photography is an inexpensive and simple test to identify neovascularization regions when compared to Optical Coherence Tomography and Fluorescein Angiography. Yet, there are no robust methods in the industry that deems to be a benchmark in neovascularization identification. This paper highlights a novel and a robust methodology for neovascularization detection. It incorporates image processing methods and machine learning techniques to segment the regions with neovascularization.

Stuff to Read

  • Automatic eye screening is a cutting-edge method that leverages technology and automated processes to assess the health of an individual's eyes. It involves specialized equipment and software to detect eye conditions such as myopia, hyperopia, glaucoma, diabetic retinopathy, and more. Automating the screening process, streamlines the evaluation, enabling early detection and timely intervention, which is crucial for maintaining good vision and preventing vision-related problems.

    This approach is typically employed in clinical settings, like eye clinics and optometrist offices, facilitating quicker and more precise assessments. It not only improves the accessibility of eye care but also contributes to the overall quality of healthcare by ensuring that eye conditions are identified and managed effectively, enhancing the chances of preserving and enhancing a person's visual health.

  • Diabetic Retinopathy (DR) is one of the fastest growing causes of blindness in the world which occurs due to a complication of Diabetes. Approximately 463 million people in the world suffer from Diabetes and each one of them has a risk of going blind due to DR. It is caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). The longer you have Diabetes and the less controlled your blood sugar is, the more likely you are to develop this eye complication.In the beginning, Diabetic Retinopathy may exhibit no symptoms or only mild vision problems. However, if left untreated it can eventually cause complete blindness. The condition can develop in anyone who has been diagnosed with type 1 or type 2 Diabetes. Diabetic Retinopathy affects up to 80% of patients who suffer from Diabetes for over 20 years. Each year in the United States, Diabetic Retinopathy accounts for 12% of all new cases of blindness. It is also the leading cause of blindness in people aged 20 to 64. Of these cases, at least 90% of new cases could be reduced with proper treatment and monitoring of the eyes. The key to prevent blindness is regular screening (once a year as recommended by medical officers worldwide) because this condition is asymptomatic, i.e. the condition develops without any symptoms at first and the patient may get to a point of vision loss at the final stage of the disease which is irreversible.

    DR can be diagnosed by visual examination of retinal images to detect most common pathological features such as microaneurysms, hemorrhage, exudates and neovascularization. This process is manual and time consuming and the outcomes depend on the examiner’s perspective. Thus, there's a potential bias in the examiner’s decision.Once the pathological signs are identified, these examinations can be used to identify different disease stages such as “No DR”, “Moderate DR’’, “Proliferative DR” etc.

  • With the increasing number of Diabetic patients in the world, the need for eye screening is growing worldwide. A shortage of ophthalmologists who are expertized in eye screening has become a major problem worldwide. In a US study, it was estimated that by 2029, around 20% of the American population will be over the age of sixty-five. Therefore, it has been presumed that the demand for ophthalmology care in the next two decades will be higher than ever before because diseases like cataracts, glaucoma, macular degeneration and DR are all age-related eye diseases.

    Furthermore, it is expected that the number of DR patients will rise upto 191 million by 2030. Even in rural areas of Sri Lanka, a shortage of doctors who are specialized in eye screening can be seen. Also, eye screening and having an appointment with a specialized doctor to diagnose the disease condition can be very costly. Even if the patient consults a doctor, the doctor’s decision can be inconsistent. I.e there can be a variability or disagreement about the different stages of DR (eg. No disease, moderate, severe etc.) from different doctors. Because of these issues, about half of people suffer from vision loss even before they are diagnosed with the disease condition. Hence AES with very high accuracy is a much needed cost-effective solution to overcome this global situation.

  • Even Though several companies have done researches on Automatic Diabetic retinopathy detection, these companies have only focussed on identifying the severity of DR using retinal images, i.e. the different stages of disease progression from “no DR to proliferative DR”. What distinguishes Ophtha AES software from the others is that our system not only detects the severity of the disease but also detects pathological features of DR and marks their specific locations in the retinal image. For this, the system is trained with over +45000 retinal images at several stages. The following images show how the pathological features are identified by the system.

Contact Us

Fill this form and we'll get back to you soon.


32, Wijayaba Mawatha, Colombo, 11222, Sri Lanka


+94 76 621 0120